secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001558370-23-006520
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase Therapeutics changes fiscal year-end from Sept 30 to Dec 31 effective 2023
--------------------------------------------------------------------------------

- Board approved change on April 21, 2023, aligning fiscal year with calendar year.
- Fiscal year beginning Jan 1, 2023 will end Dec 31, 2023; transitional 10-QT for Oct-Dec 2022.
- Reason: better alignment with the Company's planning cycles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000155837023006520/0001558370-23-006520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000155837023006520/tmb-20230421x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-006520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer